NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$3.0b

Last Updated

2021/05/12 22:06 UTC

Data Sources

Company Financials +

Executive Summary

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Reata Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RETA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: RETA's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-10.3%

RETA

-0.01%

US Pharmaceuticals

-2.8%

US Market


1 Year Return

-45.8%

RETA

11.4%

US Pharmaceuticals

49.4%

US Market

Return vs Industry: RETA underperformed the US Pharmaceuticals industry which returned 11.1% over the past year.

Return vs Market: RETA underperformed the US Market which returned 48.6% over the past year.


Shareholder returns

RETAIndustryMarket
7 Day-10.3%-0.01%-2.8%
30 Day-4.9%3.6%-2.3%
90 Day-33.5%0.5%-1.3%
1 Year-45.8%-45.8%15.3%11.4%51.8%49.4%
3 Year154.9%154.9%33.6%23.4%57.5%47.6%
5 Yearn/a47.6%29.5%121.7%97.1%

Long-Term Price Volatility Vs. Market

How volatile is Reata Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Reata Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

8.02x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RETA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RETA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RETA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: RETA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RETA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RETA is overvalued based on its PB Ratio (8x) compared to the US Pharmaceuticals industry average (3.5x).


Future Growth

How is Reata Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

59.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RETA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RETA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RETA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RETA's revenue (69.4% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: RETA's revenue (69.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RETA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Reata Pharmaceuticals performed over the past 5 years?

-59.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RETA is currently unprofitable.

Growing Profit Margin: RETA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RETA is unprofitable, and losses have increased over the past 5 years at a rate of 59.6% per year.

Accelerating Growth: Unable to compare RETA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RETA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.02%).


Return on Equity

High ROE: RETA has a negative Return on Equity (-72.09%), as it is currently unprofitable.


Financial Health

How is Reata Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: RETA's short term assets ($805.5M) exceed its short term liabilities ($114.4M).

Long Term Liabilities: RETA's short term assets ($805.5M) exceed its long term liabilities ($331.4M).


Debt to Equity History and Analysis

Debt Level: RETA is debt free.

Reducing Debt: RETA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RETA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RETA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 43.6% each year.


Dividend

What is Reata Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RETA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RETA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RETA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RETA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RETA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

J. Huff (66 yo)

19.33yrs

Tenure

US$5,542,605

Compensation

Mr. J. Warren Huff has been the Chief Executive Officer and President of Reata Pharmaceuticals, Inc. (formerly, Reata Discovery Inc) since founding in 2002 and has been its Chairman since 2002. Mr. Huff is...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD5.54M) is about average for companies of similar size in the US market ($USD5.33M).

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RETA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: RETA's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.1%.


Top Shareholders

Company Information

Reata Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Reata Pharmaceuticals, Inc.
  • Ticker: RETA
  • Exchange: NasdaqGM
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.013b
  • Shares outstanding: 36.28m
  • Website: https://www.reatapharma.com

Number of Employees


Location

  • Reata Pharmaceuticals, Inc.
  • 5320 Legacy Drive
  • Plano
  • Texas
  • 75024
  • United States

Listings


Biography

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cel...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/12 22:06
End of Day Share Price2021/05/12 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.